Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 11/20 | 1.00 |
| ▸ | MMP9 | P14780 | 11/20 | 1.00 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7475919 | 0.93 | MMP2 (0.87) | MMP2MMP9MMP13ADAM17CRBN | |
| SCHEMBL12273398 | 0.91 | MMP2 (0.84) | MMP2MMP9MMP13ADAM17ABCG2 | |
| SCHEMBL8471189 | 0.89 | MMP2 (0.80) | MMP2MMP9MMP13ADAM17 | |
| SCHEMBL4664602 | 0.84 | MMP2 (0.72) | MMP2MMP9MMP13ADAM17 | |
| SCHEMBL6447921 | 0.82 | MMP2 (0.70) | MMP2MMP9MMP13ADAM17 | |
| SCHEMBL4664591 | 0.82 | MMP2 (0.69) | MMP2MMP9MMP13ADAM17 | |
| SCHEMBL5924548 | 0.81 | MMP2 (1.00) | MMP2MMP9MMP13ADAM17 | |
| SCHEMBL4664508 | 0.79 | MMP2 (0.66) | MMP2MMP9MMP13ADAM17 | |
| SCHEMBL7474147 | 0.79 | MMP2 (0.64) | MMP2MMP9MMP13 | |
| SCHEMBL4663104 | 0.78 | MMP2 (0.64) | MMP2MMP9MMP13ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221991-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER METASTASES | UNIVERSITY OF CINCINNATI (US) | 2025-07-10 | — | — | US | claimed |
| US-20230101403-A1 | METHOD OF TREATING OR AMELIORATING CANCERS DRIVEN BY RECEPTOR TYROSINE KINASE FUSION ONCOGENES, AND COMPOSITIONS FOR THE SAME | UNIV PENNSYLVANIA (US) | 2023-03-30 | — | — | US | claimed |
| US-8044035-B2 | Pharmaceutical compositions of pyrimidine-2,4,6-triones | UNIVERSITE DE LIEGE (BE) | 2011-10-25 | — | — | US | claimed |
| JP-4787240-B2 | — | — | 2011-10-05 | — | — | JP | claimed |
| US-20100261672-A1 | PHARMACEUTICAL COMPOSITIONS OF PYRIMIDINE-2,4,6-TRIONES | UNIVERSITE DE LIEGE (BE) | 2010-10-14 | — | — | US | claimed |
| EP-1737464-B1 | USE OF A TRIOXOPYRIMIDINE FOR THE TREATMENT AND PREVENTION OF BRONCHIAL INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | claimed |
| US-20070225253-A1 | Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | US | claimed |
| US-20070191404-A1 | Pharmaceutical compositions of pyrimidine-2,4,6-triones | HOFFMANN-LA ROCHE INC. | 2007-08-16 | — | — | US | claimed |
| EP-1735007-A2 | CYCLODEXTRIN INCLUSION COMPLEXES OF PYRIMIDINE-2,4,6-TRIONES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-27 | — | — | EP | claimed |
| WO-2005097058-A2 | CYCLODEXTRIN INCLUSIONS COMPLEXES OF PYRIMIDINE-2,4,6-TRIONES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-20 | — | — | WO | claimed |
| WO-2004084902-A1 | USE OF A TRIOXOPYRIMIDINE FOR THE TREATMENT OF CHRONIC WOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | claimed |
| EP-3226909-B1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3964242-B1 | SURGICAL STAPLER WITH END EFFECTOR COATING | CILAG GMBH INT (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20250221991-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER METASTASES | UNIVERSITY OF CINCINNATI (US) | 2025-07-10 | — | — | US | disclosed |
| US-11992216-B2 | Surgical stapler with end effector coating | CILAG GMBH INTERNATIONAL (CH) | 2024-05-28 | — | — | US | disclosed |
| WO-2004110457-A1 | MATRIX METALLOPROTEINASES INHIBITORS FOR THE STIMULATION AND PROTECTION OF BONE MARROW STEM CELLS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004084902-A1 | USE OF A TRIOXOPYRIMIDINE FOR THE TREATMENT OF CHRONIC WOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084903-A1 | USE OF A TRIOXOPYRIMIDINE FOR THE TREATMENT AND PREVENTION OF OCULAR PATHOLOGIC ANGIOGENESIS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004037286-A2 | COMBINATION OF A TRIOXOPYRIMIDINE COMPOUND INHIBITOR AND AN ANTI-TUMOR AGENT, AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191404-A1 | Pharmaceutical compositions of pyrimidine-2,4,6-triones | TK1, TYMP, TYMS | MMP2 4254/4885MMP9 4163/4885MMP13 4515/4885 |
| US-20040138276-A1 | Metalloproteinase inhibitors | MMP9, MMP11, MMP7 | MMP2 8/4885MMP9 1/4885MMP13 7/4885 |
| US-20100261672-A1 | PHARMACEUTICAL COMPOSITIONS OF PYRIMIDINE-2,4,6-TRIONES | TYMP, DPYD, TYMS | MMP2 4282/4885MMP9 4156/4885MMP13 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.